

Targeted Sequencing Publications Featuring Access Array™ System

As of November 2015

Biomarker Screening

Paliwal, A, Temkin, A.M., Kerkel, K. et al. "Comparative anatomy of chromosomal domains with imprinted and non-imprinted allele-specific DNA methylation." *PLoS Genetics* 9(8) (2013): e1003622.

Schueler, M., Braun, D.A., Chandrasekar, G. et al. "DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling." *American Journal of Human Genetics* 96(1) (2015): 81–92.

Fingerprinting and Sample Identification

Curk, F., Ancillo, G., Garcia-Lor, A. et al. "Next generation haplotyping to decipher nuclear genomic interspecific admixture in Citrus species: analysis of chromosome 2." *BMC Genetics* (2014): 152.

Isaacson, J., Schwoebel, E., Shcherbina, A. et al. "Robust detection of individual forensic profiles in DNA mixtures." *Forensic Science International: Genetics* 14 (2015): 31–37.

HLA Typing

Lange, V., Böhme, I., Hofmann, J. et al. "Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing." *BMC Genomics* (2014): 63.

Moonsamy, P.V., Williams, T., Bonella, P. et al. "High throughput HLA genotyping using 454 sequencing and the Fluidigm Access Array System for simplified amplicon library preparation." *Tissue Antigens* 81(3) (2013): 141–149.

Yamamoto, F., Höglund, B., Fernandez-Vina, M. et al. "Very high resolution single pass HLA genotyping using amplicon sequencing on the 454 next generation DNA sequencers: Comparison with Sanger sequencing." *Human Immunology* (2015): doi:10.1016/j.humimm.2015.05.002.

Immunology

Hunt, K.A., Mistry, V., Bockett, N.A. et al. "Negligible impact of rare autoimmune-locus coding-region variants on missing heritability." *Nature* 498(7453) (2013): 232–235.

Lange, V., Boehme, I., Paul, P. et al. "LBOR01: One million samples typed by NGS – lessons learned." *Human Immunology* (2015): doi:10.1016/j.humimm.2015.01.030.

Inherited Disease

Bronicki, L.M., Redin, C., Drunat, S. et al. "Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in *DYRK1A*." *European Journal of Human Genetics* 23(11) (2015): 1,482–1,487.

Cordeddu, V., Yin, J.C., Gunnarsson, C. et al. "Activating mutations affecting the Dbl homology domain of *SOS2* cause Noonan syndrome." *Human Mutation* 36(11) (2015): 1,080–1,087.

Coutelier, M., Goizet, C., Durr, A. et al. "Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia." *Brain* 138(8) (2015): 2,191–2,205.

Halbritter, J., Diaz, K., Chaki, M. et al. "High-throughput mutation analysis in patients with a nephronophthisis-associated ciliopathy applying multiplexed barcoded array-based PCR amplification and next-generation sequencing." *Journal of Medical Genetics* 49(12) (2012): 756–767.

Halbritter, J., Porath, J., Diaz, K. et al. "Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy." *Human Genetics* 132(8) (2013): 865–884.

Hollants, S., Redeker, E.J., Matthijs, G. "Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes." *Clinical Chemistry* 58(4) (2012): 717–724.

Hsu, A.L., Kondrashova, O., Lunke, S. et al. "AmpliVar: mutation detection in high-throughput sequence from amplicon-based libraries." *Human Mutation* 36(4) (2015): 411–418.

Hwang, D.Y., Kohl, S., Fan, X. et al. "Mutations of the *SLIT2*–*ROBO2* pathway genes *SLIT2* and *SRGAP1* confer risk for congenital anomalies of the kidney and urinary tract." *Human Genetics* 134(8) (2015): 905–916.

Jones, M.A., Bhide, S., Chin, E. et al. "Targeted PCR-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation (CDG)." *Genetics in Medicine* 13(11) (2011): 921–932.

Li X., Buckton A.J., Wilkinson S.L. et al. "Towards clinical molecular diagnosis of inherited cardiac conditions: a comparison of bench-top genome DNA sequencers." *PLoS ONE* 8(7) (2013): e67744.

Schlipf, N.A., Schüle, R., Klimpe, S. et al. "Amplicon-based high-throughput pooled sequencing identifies mutations in *CYP7B1* and *SPG7* in sporadic spastic paraplegia patients." *Clinical Genetics* 80(2) (2011): 148–160.

Verdura, E., Hervé, D., Scharrer, E. et al. "Heterozygous *HTRA1* mutations are associated with autosomal dominant cerebral small vessel disease." *Brain* 138(8) (2015): 2,347–2,358.

Zernant, J., Schubert, C., Im, K.M. et al. "Analysis of the *ABCA4* gene by next-generation sequencing." *Investigative Ophthalmology & Visual Science* 52(11) (2011): 8,479–8,487.

Liquid Biopsy

Madic, J., Kiialainen, A., Bidard, F.C. et al. "Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients." *International Journal of Cancer* 136(9) (2015): 2,158–2,165.

Microbiology and Viral Pathogen Detection

Aizenberg-Gershtein, Y., Izhaki, I., Santhanam, R. et al. "Pyridine-type alkaloid composition affects bacterial community composition of floral nectar." *Scientific Reports* (2015): doi:10.1038/srep11536.

Bhatia, S., Batra, N., Pathak, A. et al. "Metagenomic evaluation of bacterial and archaeal diversity in the geothermal hot springs of Manikaran, India." *Genome Announcements* 3(1) (2015): e01544-14.

Hermann-Bank, M.L., Skovgaard, K., Stockmarr, A. et al. "The Gut Microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity." *BMC Genomics* (2013): 788.

Sahoo, M.K., Lefterova, M.I., Yamamoto, F. et al. "Detection of cytomegalovirus drug resistance mutations by next-generation sequencing." *Journal of Clinical Microbiology* 51(11) (2013): 3,700–3,710.

Wright, C., Akraiko, T., Hernandez, A. et al. "Multi-targeted community profiling: leveraging the Fluidigm Access Array and Illumina MiSeq for metagenomic sequencing—microorganisms." Abstract P0046, International Plant & Animal Genome Conference. *Plant and Animal Genome* (2015): pag.confex.com/pag/xxiii/webprogram/Paper15562.html.

Yue, M., Schmieder, R., Edwards, R.A. et al. "Microfluidic PCR combined with pyrosequencing for identification of allelic variants with phenotypic associations among targeted Salmonella genes." *Applied and Environmental Microbiology* 78(20) (2012): 7,480–7,482.

Oncology

Aitken, S.J., Presneau, N., Kalimuthu, S. et al. "Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses." *Virchows Archiv* 467(2) (2015): 203–210.

Atwood, S.X., Sarin, K.Y., Whitson, R.J. et al. "Smoothed variants explain the majority of drug resistance in basal cell carcinoma." *Cancer Cell* 27(3) (2015): 342–353.

Bourgon, R., Lu, S., Yan, Y. et al. "High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing." *Clinical Cancer Research* 20(8) (2014): 2,080–2,091.

Chang, F., Li, M.M. "Clinical application of amplicon-based next-generation sequencing in cancer." *Cancer Genetics* 206(12) (2013): 413–419.

Chen, J., Wang, Y., McMonechy, M.K. et al. "Recurrent *DICER1* hotspot mutations in endometrial tumours and their impact on microRNA biogenesis." *The Journal of Pathology* 237(2) (2015): 215–225.

Dawson, S.-J., Tsui, D.W., Murtaza, M. et al. "Analysis of circulating tumor DNA to monitor metastatic breast cancer." *The New England Journal of Medicine* 368(13) (2013): 1,199–1,209.

De Leeneer, K., Hellemans, J., Steyaert, W. et al. "Flexible, scalable, and efficient targeted resequencing on a benchtop sequencer for variant detection in clinical practice." *Human Mutation* 36(3) (2015): 379–387.

Do, H., Dobrovic, A. "Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase." *Oncotarget* 3(5) (2012): 546–558.

Domagala, P., Jakubowska, A., Jaworska-Bieniek, K. et al. "Prevalence of germline mutations in genes engaged in DNA damage repair by homologous recombination in patients with triple-negative and hereditary non-triple-negative breast cancers." *PLoS ONE* 10(6) (2015): e0130393.

Forsheo, T., Murtaza, M., Parkinson, C. et al. "Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA." *Science Translational Medicine* 4(136) (2012): 136ra68.

Giannakis, M., Hodis, E., Mu, X.J. et al. "RNF43 is frequently mutated in colorectal and endometrial cancers." *Nature Genetics* 46(12) (2014): 1,264–1,266.

Gossage, L., Murtaza, M., Slatter, A.F. et al. "Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma." *Genes, Chromosomes and Cancer* 53(1) (2014): 38–51.

Grossmann, V., Kohlmann, A., Eder, C. et al. "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance." *Leukemia* 25(5) (2011): 877–879.

Hoang, L.N., McConechy, M.K., Köbel, M. et al. "Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma." *International Journal of Gynecological Cancer* 25(7) (2015): 1,187–1,193.

Izumchenko, E., Sun, K., Jones, S. et al. "Notch1 mutations are drivers of oral tumorigenesis." *Cancer Prevention Research* 8(4) (2015): 277–286.

Jiang, L., Huang, J., Morehouse, C. et al. "Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients." *Cancer Genetics* 206(9-10) (2013): 330–339.

Korbie, D., Lin, E., Wall, D. et al. "Multiplex bisulfite PCR resequencing of clinical FFPE DNA." *Clinical Epigenetics* (2015): 28.

Kuhn, A., Ong, Y.M., Quake, S.R. et al. "Read count-based method for high-throughput allelic genotyping of transposable elements and structural variants." *BMC Genomics* (2015): 508.

Kukurba, K.R., Zhang, R., Li, X. et al. "Allelic expression of deleterious protein-coding variants across human tissues." *PLoS Genetics* 10(5) (2014): e1004304.

Kwong, A., Chen, J., Shin, V.Y. et al. "The importance of analysis of long-range rearrangement of *BRCA1* and *BRCA2* in genetic diagnosis of familial breast cancer." *Cancer Genetics* 208(9) (2015): 448–454.

Li, Z., Guo, X., Wu, Y. et al. "Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients." *Breast Cancer Research and Treatment* 149(3) (2015): 767–779.

Lohr, J.G., Stojanov, P., Lawrence, M.S. et al. "Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing." *Proceedings of the National Academy of Sciences* 109(10) (2012): 3,879–3,884.

McConechy, M.K., Hoang, L.N., Chui, M.H. et al. "In-depth molecular profiling of the biphasic components of uterine carcinosarcomas." *The Journal of Pathology: Clinical Research* 1(3) (2015): 173–185.

Murphy, D.A., Scott, C., Fitzgerald, K. et al. "Identification of critical steps involved in optimization of next generation sequencing (NGS) using a retrospective meta-analysis of a large clinical testing cohort." Abstract 5601, Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. *Cancer Research* (2014): doi:10.1158/1538-7445.AM2014-5601.

Ng, C.C., Tan, J., Ong, C.K. et al. "*MED12* is frequently mutated in breast phyllodes tumours: a study of 112 cases." *Journal of Clinical Pathology* 68(9) (2015): 685–691.

Presneau, N., Baumhoer, D., Behjati, S. et al. "Diagnostic value of *H3F3A* mutations in giant cell tumour of bone compared to osteoclast-rich mimics." *The Journal of Pathology: Clinical Research* 1(2) (2015): 113–123.

Ryner, L., Guan, Y., Firestein, R. et al. "Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer." *Clinical Cancer Research* 21(13) (2015): 2,941–2,951.

Schwarz, R.F., Ng, C.K., Cooke, S.L. et al. "Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis." *PLoS Medicine* 12(2) (2015): e1001789.

Shen, J., LeFave, C., Sirosh, I. et al. "Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas." *BMC Medical Genomics* (2015): 28.

Song, H., Cicek, M.S., Dicks, E. et al. "The contribution of deleterious germline mutations in *BRCA1*, *BRCA2* and the mismatch repair genes to ovarian cancer in the population." *Human Molecular Genetics* 23(17) (2014): 4,703–4,709.

Tone, A.A., McConechy, M.K., Yang, W. et al. "Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas." *BMC Cancer* (2014): 982.

Wang M., Escudero-Ibarz L., Moody S. et al. "Somatic mutation screening using archival formalin-fixed, paraffin-embedded tissues by Fluidigm multiplex PCR and Illumina sequencing." *The Journal of Molecular Diagnostics* 17(5) (2015): 521–532.

Weißbach, S., Langer, C., Puppe, B. et al. "The molecular spectrum and clinical impact of *DIS3* mutations in multiple myeloma." *British Journal of Haematology* 169(1) (2015): 57–70.

Wong, S.Q., Li, J., Tan, A.Y. et al. "Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing." *BMC Medical Genomics* (2014): 23.

Zhang, R., Li, X., Ramaswami, G. et al. "Quantifying RNA allelic ratios by microfluidic multiplex PCR and sequencing." *Nature Methods* 11(1) (2014): 51–54.

Population Screening

Jones, M.R., Good, J.M. "Targeted capture in evolutionary and ecological genomics." *Molecular Ecology* (2015): doi:10.1111/mec.13304.

Jordon-Thaden, I., Uribe-Convers, S., Godden, G.T. et al. "A research workflow for development of single-copy nuclear loci and high-throughput targeted enrichment for two or more phylogenetic studies." Abstract 811, Botany 2014. Botanical Society of America: 2014.botanyconference.org.

Mistry, V., Bockett, N.A., Levine, A.P. et al. "Exome sequencing of 75 individuals from multiply affected coeliac families and large scale resequencing follow up." *PLoS ONE* 10(1) (2015): e0116845.

CORPORATE HEADQUARTERS

7000 Shoreline Court, Suite 100
South San Francisco, CA 94080 USA
Toll-free: 866 359 4354 in the US
Fax: +1 650 871 7152
fluidigm.com

SALES

North America | +1 650 266 6170 | info-us@fluidigm.com
Europe/EMEA | +33 1 60 92 42 40 | info-europe@fluidigm.com
China (excluding Hong Kong) | +86 21 3255 8368 | info-china@fluidigm.com
Japan | +81 3 3662 2150 | info-japan@fluidigm.com
All other Asian countries | +1 650 266 6000 | info-asia@fluidigm.com
Latin America | +1 650 266 6000 | info-latinamerica@fluidigm.com

For Research Use Only. Not for use in diagnostic procedures.

© 2015 Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, and Access Array are trademarks or registered trademarks of Fluidigm Corporation in the US and/or other countries. 11/2015